TABLE 1.
Summary of case series showing sample size, nature of biopsies, median follow up, prevalence of TG, graft loss
| Sr no. | Series reference | Sample size | Nature of biopsies | Median follow up (months) | Prevalence of TG; N and percentage | Graft loss rate; percentage | Notes |
|---|---|---|---|---|---|---|---|
| 1. | Suri et al4 | 406 | Retrospective review of biopsies with TG | Review of biopsies with TG in a course of 4 years in a single center | 25 (6.1%) | 12% (4 years) | TG patients had increased rate of graft loss when compared to chronic rejection |
| 2. | Banfi et al6 | 666 | Clinically indicated | 120 months | 28 (5.6%) | 52% (120 months) | Incidence and clinical course of TG is not modified by CNI based immunosuppression |
| 3. | Kamal et al7 | 525 | Clinically indicated | 23 (1–46) months after biopsy | 52 (10%) | 32% (23 months after diagnosis) | Graft loss is associated with increased expression of ENDAT |
| 4. | Gloor et al8 | 582 | Surveillance and clinically indicated | 41–61 months after transplant | −55 (9.5%) at 2 years −117 (20%) at 5 years |
27% (3½ years) | Subclinical TG had similar poor prognosis as TG highlighting importance of subclinical TG in graft dysfunction |
| 5. | Patri et al9 | 1606 | Surveillance and clinically indicated | 60 months from diagnosis | 92 (6%) | 70% (60 months after diagnosis) | Development of prognostic index to predict prognosis of TG |
| 6. | Aubert et al10 | 8207 | Surveillance and clinically indicated | 33 months from time of transplant to development of TG | 552 (6.7%) | 74.5% (10 years) | Probabilistic data-driven archetype analysis approach refines the diagnostic and prognostic features associated with cases of TG |
| 7. | Sharif et al13 | 124 | Surveillance and clinically indicated | 42 months post biopsy | 31 (25%) in desensitized patients | 33.3 (42 months after diagnosis) | Incidence of TG was 25% biopsies from patients with HLA-incompatible desensitized renal transplant patients |
| 8. | Shimizu et al16 | 86 | Clinically indicated | Retrospective analysis of TG | only TG biopsies reported in study | 22% (72 months) | Most common pathologic finding was peritubular capillaritis |
| 9. | Sis et al17 | 1036 | Clinically indicated | Retrospective review | 53 (5.1%) | NA | Transplant glomerulopathy has evidence of alloantibody-mediated injury |
| 10 | Lesage et al18 | 61 | Clinically indicated | Retrospective review | Only TG biopsies reported in study | 16% (48 months) | TG is associated with poor prognosis whether there is evidence of tissue or peripheral alloantibody reactivity |
| 11. | Issa et al23 | 598 | Surveillance and clinically indicated | 54 months | 73 (12%) | 25% TG/C4D- and 80% TG/C4d+ (54 months) | Higher anti-HLA-II antibody levels are related to increase risk of developing TG |
| 12. | Joosten et al32 | 16 | Surveillance and clinically indicated | Retrospective Review | only TG biopsies with similar controls reported in study | NA | Humoral response of Glomerular Basement heparan sulfate proteoglycans agrin (GBM-HSPG) may play a role in pathogenesis of TG |
| 13. | Akalin et al39 | 428 | Clinically indicated | Retrospective Review | 36 (7%) TG + CAN | NA | Non-alloantibody-mediated process may be involved in the development of TGP in some patients |
| 14. | Homs et al41 | 35 | Clinically indicated | Retrospective Review | Only TG biopsies with similar controls reported in study | NA | Results indicate a role of an active T-mediated inflammatory and cytotoxic process in the pathogenesis of TGP |
| 15. | Li et al50 | 1587 | Surveillance and clinically indicated | 60 months | 180 (11%) | 65% (60 months after diagnosis) | ci + ct and cg at biopsy were predictors of unfavorable prognosis |
Note: The percentage of graft loss is reported from time of transplant unless otherwise indicated.